Higher ADK levels track stronger triciribine effects in leukemia cells, pointing to a potential biomarker

Researchers at Karolinska Institutet report that ADK levels are associated with how acute lymphoblastic leukemia cells respond to triciribine. The study, published in npj Precision Oncology, suggests ADK could serve as a biomarker for predicting the compound’s effects.